CR8302A - Compuestos heterociclicos fusionados - Google Patents

Compuestos heterociclicos fusionados

Info

Publication number
CR8302A
CR8302A CR8302A CR8302A CR8302A CR 8302 A CR8302 A CR 8302A CR 8302 A CR8302 A CR 8302A CR 8302 A CR8302 A CR 8302A CR 8302 A CR8302 A CR 8302A
Authority
CR
Costa Rica
Prior art keywords
fusioned
heterociclic compounds
heterociclic
compounds
seratonin
Prior art date
Application number
CR8302A
Other languages
English (en)
Spanish (es)
Inventor
Mani Neelakandha
I Carruthers Nicholas
Chai Wenying
Deng Xiaohu
A Dvorak Curt
K Kwok Annette
A Rudolph Dale
D Wong Victoria
T Liang Jimmy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34526458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8302(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR8302A publication Critical patent/CR8302A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR8302A 2003-09-17 2006-03-17 Compuestos heterociclicos fusionados CR8302A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50452803P 2003-09-17 2003-09-17
US55267304P 2004-03-11 2004-03-11

Publications (1)

Publication Number Publication Date
CR8302A true CR8302A (es) 2008-09-10

Family

ID=34526458

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8302A CR8302A (es) 2003-09-17 2006-03-17 Compuestos heterociclicos fusionados

Country Status (29)

Country Link
US (5) US7402680B2 (https=)
EP (1) EP1668014B1 (https=)
JP (1) JP5069907B2 (https=)
KR (1) KR101151653B1 (https=)
CN (1) CN103788089A (https=)
AR (1) AR047218A1 (https=)
AT (1) ATE420881T1 (https=)
AU (1) AU2004283196B2 (https=)
BR (1) BRPI0414541B8 (https=)
CA (1) CA2539426C (https=)
CL (1) CL2009000943A1 (https=)
CR (1) CR8302A (https=)
CY (1) CY1109416T1 (https=)
DE (1) DE602004019118D1 (https=)
DK (1) DK1668014T3 (https=)
EA (2) EA010905B1 (https=)
EC (1) ECSP066436A (https=)
ES (1) ES2319539T3 (https=)
IL (2) IL174283A (https=)
IS (1) IS2756B (https=)
MX (1) MXPA06003150A (https=)
NI (1) NI200600094A (https=)
NZ (1) NZ545836A (https=)
PL (1) PL1668014T3 (https=)
PT (1) PT1668014E (https=)
SG (1) SG146683A1 (https=)
SI (1) SI1668014T1 (https=)
TW (1) TWI345565B (https=)
WO (1) WO2005040169A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1668014T1 (sl) * 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
US20080161419A1 (en) * 2004-02-20 2008-07-03 Shinobu Akuzawa Prophylactic Antimigraine Agents
CA2565683C (en) * 2004-06-30 2013-04-02 Athersys, Inc. Substituted azepine derivatives as serotonin receptor modulators
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP1852129A4 (en) * 2005-02-08 2009-07-15 Astellas Pharma Inc REMEDIES FOR IRRITATION SYNDROME
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
GB0513886D0 (en) * 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
CN101277700B (zh) * 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US8076348B2 (en) * 2005-08-08 2011-12-13 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
BRPI0707183A2 (pt) * 2006-01-19 2011-04-26 Athersys Inc composto, composição farmacêutica, e, método de tratar uma doença, distúrbio e/ou condição em um paciente
US8012957B2 (en) 2006-03-27 2011-09-06 Janssen Pharmaceutica Nv Tetrahydro-1H-1,2,6-triaza-azulene cannabinoid modulators
DE602007005117D1 (de) * 2006-05-05 2010-04-15 Janssen Pharmaceutica Nv Herstellungsverfahren für pyrazolhaltige verbindungen
WO2008026149A1 (en) * 2006-08-28 2008-03-06 Actelion Pharmaceuticals Ltd 1,4,5,6, 7,8-hexahydro-i^1s-triaza-azulene derivatives as orexin receptor antagonists
WO2009058810A1 (en) * 2007-11-02 2009-05-07 Janssen Pharmaceutica N.V. Process for the preparation of substituted 2,4,5,6,7,8-hexahydro-1,2,6-triaza-azulene derivatives
EP2229361A1 (en) 2008-01-03 2010-09-22 Allergan, Inc. Tetrahydroindoles having sphingosine-1-phosphate receptor activity
US8829011B2 (en) 2008-10-29 2014-09-09 Janssen Pharmaceutica Nv 2-aminopyrimidine compounds as serotonin receptor modulators
KR101385433B1 (ko) 2008-11-18 2014-04-14 에프. 호프만-라 로슈 아게 다이하이드로테트라아자벤조아줄렌의 알킬사이클로헥실에터
EP2370437B1 (en) * 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
TWI410418B (zh) * 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
GB201004311D0 (en) 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EP2699563B3 (en) 2011-04-21 2024-06-12 Basf Se Novel pesticidal pyrazole compounds
EP2755974A1 (en) 2011-09-14 2014-07-23 Proximagen Limited New enzyme inhibitor compounds
WO2013156318A1 (en) 2012-04-16 2013-10-24 Basf Se Substituted pesticidal pyrazole compounds
US9474277B2 (en) 2012-06-20 2016-10-25 Basf Se Pyrazole compound and pesticidal mixtures comprising a pyrazole compound
CA2882127A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers
WO2014063942A1 (en) 2012-10-23 2014-05-01 Basf Se Substituted pesticidal pyrazole compounds
JP2016503808A (ja) 2012-12-21 2016-02-08 エイビーティー ホールディング カンパニー セロトニン５−ＨＴ２ｃ受容体リガンドとしてのベンザゼピンおよびその使用
US9309262B2 (en) 2013-03-13 2016-04-12 Abt Holding Company Thienylindole azepines as serotonin 5-HT2C receptor ligands and uses thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
WO2015055497A1 (en) 2013-10-16 2015-04-23 Basf Se Substituted pesticidal pyrazole compounds
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
EP3256450B1 (en) * 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
CN105503647A (zh) * 2015-12-10 2016-04-20 苏州昊帆生物科技有限公司 环丙基肼盐酸盐的制备方法
WO2017175045A1 (en) * 2016-04-08 2017-10-12 The Hong Kong Polytechnic University Pyrimidines for treatment of bacterial infections
KR101917264B1 (ko) 2016-12-22 2018-11-13 한국과학기술연구원 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
KR102037494B1 (ko) 2017-12-11 2019-10-28 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
WO2019137995A1 (en) 2018-01-11 2019-07-18 Basf Se Novel pyridazine compounds for controlling invertebrate pests
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
KR20190120112A (ko) 2019-10-08 2019-10-23 씨제이헬스케어 주식회사 광학활성을 갖는 피페리딘 유도체의 중간체 및 이의 제조방법
JP2023511302A (ja) * 2020-01-13 2023-03-17 アプタバイオ セラピューティクス インコーポレイテッド 新規なピラゾール誘導体
CN119841865A (zh) 2020-02-07 2025-04-18 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4211139A4 (en) 2020-09-10 2024-12-18 Gasherbrum Bio, Inc. HETEROCYCLIC GLP-1 AGONISTS
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1197466B (de) 1962-03-22 1965-07-29 Thomae Gmbh Dr K Verfahren zur Herstellung von neuen 5, 6, 7, 8-Tetrahydropyrido-[4, 3-d]pyrimidinen
US3312716A (en) 1964-08-11 1967-04-04 Aldrich Chem Co Inc 4-hydroxy-3-pyrrolidinemethanols
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
GB1484140A (en) * 1974-04-24 1977-08-24 Wyeth John & Brother Ltd Pyrrolopyridine derivatives
US3969355A (en) 1974-11-01 1976-07-13 Morton-Norwich Products, Inc. 5-Aminoethyl-2,4-diphenylpyrimidine dihydrobromide
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK27383A (da) * 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
US4576604A (en) 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4857330A (en) 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
JPH03148265A (ja) 1989-11-01 1991-06-25 Sumitomo Chem Co Ltd ５，７―ジフェニル―４，６―ジアザインダン誘導体、その製造法およびそれを有効成分とする除草剤
US5137890A (en) * 1990-02-14 1992-08-11 Ortho Pharmaceutical Corporation 4-phenyl tetrahydropyrido(4,3-d)pyrimidines
US5053508A (en) 1990-03-09 1991-10-01 American Home Products Corporation Fused heterotricyclic imides with psychotropic activity and intermedrates thereof
US5648352A (en) * 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
WO1994014777A1 (en) 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
US6677310B1 (en) * 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5843912A (en) * 1994-07-06 1998-12-01 Universy Of Maryland Ring-expanded nucleosides and nucleotides
US5405848A (en) 1993-12-22 1995-04-11 Ortho Pharmaceutical Corporation Substituted thiazolylaminotetrahydropyridopyrimidines derivatives useful as platelet aggregation inhibitors
US5663178A (en) * 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
WO1995029909A1 (en) 1994-04-29 1995-11-09 Pfizer Inc. Novel acyclic and cyclic amides as neurotransmitter release enhancers
AU5317996A (en) 1995-04-18 1996-11-07 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
WO1997029097A1 (en) 1996-02-09 1997-08-14 Smithkline Beecham Plc Sulfonamide derivatives as 5ht7 receptor antagonists
TW470745B (en) * 1996-05-23 2002-01-01 Janssen Pharmaceutica Nv Hexahydro-pyrido[4,3-b]indole derivatives
JP3531169B2 (ja) 1996-06-11 2004-05-24 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
JP2000512646A (ja) 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ７受容体アンタゴニストとしてのスルホンアミド誘導体
ES2243999T3 (es) 1996-06-28 2005-12-01 Meiji Seika Kaisha Ltd. Compuestos de tetrahidrobencindol.
GB9700899D0 (en) 1997-01-17 1997-03-05 Smithkline Beecham Plc Novel treatment
US6177443B1 (en) * 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
JP2001514631A (ja) 1997-03-07 2001-09-11 ノボ ノルディスク アクティーゼルスカブ ４，５，６，７−テトラヒドロ−チエノ［３，２−ｃ］ピリジン誘導体類、それらの製造方法及び使用
EP0905136A1 (en) * 1997-09-08 1999-03-31 Janssen Pharmaceutica N.V. Tetrahydro gamma-carbolines
US5951518A (en) 1997-10-31 1999-09-14 Teleflex, Incorporated Introducing device with flared sheath end
WO1999024022A2 (en) 1997-11-10 1999-05-20 F. Hoffmann-La Roche Ag Isoquinoline derivatives for treating disorders associated with 5ht7 receptors
US6407112B1 (en) 1998-04-22 2002-06-18 Meiji Seika Kaisha, Ltd. Optically active tetrahydrobenzindole derivative
BR9911049A (pt) 1998-05-22 2001-02-06 Lilly Co Eli Terapia combinada para tratamento de depressão resistente
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
AU1321900A (en) 1998-10-23 2000-05-15 Sepracor, Inc. Compositions and methods employing r(-) fluoxetine and other active ingredients
US6245785B1 (en) 1998-11-30 2001-06-12 Warner Lambert Company Dissolution of triprolidine hydrochloride
GB9828004D0 (en) 1998-12-18 1999-02-10 Smithkline Beecham Plc Use
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
AP2005003199A0 (en) 1999-04-01 2005-03-31 Pfizer Prod Inc Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
EP1211246B1 (en) 1999-09-09 2004-02-25 Kumiai Chemical Industry Co., Ltd. Pyrimidine derivatives and herbicides containing the same
JP2003512372A (ja) 1999-10-18 2003-04-02 スミスクライン ビーチャム パブリック リミテッド カンパニー テトラヒドロベンゾインドロン誘導体、それらの製造および５−ｈｔ７受容体アンタゴニストとしてのそれらの使用
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
EP1252161A1 (en) 2000-02-04 2002-10-30 Wyeth Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor
US20040087798A1 (en) 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US6586469B2 (en) 2000-07-25 2003-07-01 Medpointe Healthcare Inc. Antihistaminic/antitussive compositions
HK1052509B (en) 2000-08-14 2007-09-07 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
ATE413878T1 (de) * 2000-09-06 2008-11-15 Ortho Mcneil Pharm Inc Methode zum bekämpfen der allergien durch verwendung von substituierten pyrazolen
US20040267010A1 (en) 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
CA2437505C (en) * 2001-02-21 2010-02-09 Janssen Pharmaceutica N.V. Isoxazoline derivatives as anti-depressants
US20020183519A1 (en) 2001-03-13 2002-12-05 Herbert Nar Antithrombotic carboxylic acid amides
DE10111842A1 (de) 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Antithrombotische Carbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
US6559174B2 (en) * 2001-03-20 2003-05-06 Merck & Co., Inc. N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
US6806380B2 (en) 2001-10-02 2004-10-19 Lexicon Pharmaceuticals, Inc. Modified safe and efficient process for the environmentally friendly synthesis of imidoesters
JP5039268B2 (ja) * 2001-10-26 2012-10-03 アベンティス・ファーマスーティカルズ・インコーポレイテツド ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
US20030199544A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
US20030199542A1 (en) * 2002-04-18 2003-10-23 Woods Keith W. Farnesyltransferase inhibitors
HRP20020452A2 (en) 2002-05-23 2004-02-29 Pliva D D 1,2-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediates for preparation thereof
JP2005528443A (ja) * 2002-05-30 2005-09-22 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｊａｋキナーゼおよびｃｄｋ２プロテインキナーゼのインヒビター
WO2004000326A1 (en) 2002-06-20 2003-12-31 H. Lundbeck A/S Combination therapy wherein a serotonin reuptake inhibitor is used
CA2493625A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
JPWO2004011467A1 (ja) 2002-07-29 2005-12-15 北興化学工業株式会社 トリアゾロピリミジン誘導体および農園芸用殺菌剤
US20040132826A1 (en) 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
EP1556360B1 (en) 2002-10-30 2008-01-23 Ciba SC Holding AG Electroluminescent device
MXPA05008137A (es) 2003-01-31 2005-09-30 Pfizer Prod Inc Antagonistas y agonistas de 5ht7.
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
GB0316128D0 (en) 2003-07-10 2003-08-13 Univ Aston Novel sulfonamide compounds
JP4679517B2 (ja) 2003-07-23 2011-04-27 エグゼリクシス， インコーポレイテッド 薬剤としてのアゼピン誘導体
SI1668014T1 (sl) 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
ATE546452T1 (de) * 2003-09-23 2012-03-15 Vertex Pharma Pyrazolopyrrolderivate als proteinkinaseinhibitoren
MXPA06003320A (es) 2003-09-24 2006-06-08 Combinatorx Inc Regimenes terapeuticos para administrar combinaciones de farmacos.
EP1696896A2 (en) 2003-12-15 2006-09-06 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
US20050232986A1 (en) 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20090227562A1 (en) 2004-08-10 2009-09-10 Pfizer Inc. Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor
US20060037652A1 (en) 2004-08-23 2006-02-23 Ranco Incorporated Of Delaware Reversing valve assembly with improved pilot valve mounting structure
EP1831173B1 (en) 2004-12-17 2011-01-26 Janssen Pharmaceutica NV Tetrahydroisoquinoline compounds for treatment of cns disorders
CA2612495A1 (en) 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Hexahydro-pyrrolo-isoquinoline compounds for the treatment of cns disorders
WO2006138714A2 (en) 2005-06-17 2006-12-28 Janssen Pharmaceutica N.V. Naphthyridine compounds
CN101277700B (zh) 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CA2646023A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
DE602007005117D1 (de) 2006-05-05 2010-04-15 Janssen Pharmaceutica Nv Herstellungsverfahren für pyrazolhaltige verbindungen
CA2656089A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Substituted benzyl amine compounds
JP2009542708A (ja) 2006-06-29 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換アミノメチルベンズアミド化合物
WO2008002817A1 (en) 2006-06-29 2008-01-03 Janssen Pharmaceutica N.V. Butyl and butynyl benzyl amine compounds
WO2008064036A1 (en) 2006-11-16 2008-05-29 Janssen Pharmaceutica N.V. Substituted phenyl propyl amines as histamine h3 receptor and serotonin transporter modulators

Also Published As

Publication number Publication date
JP2007505908A (ja) 2007-03-15
PL1668014T3 (pl) 2009-06-30
CY1109416T1 (el) 2014-08-13
BRPI0414541A8 (pt) 2019-01-02
US8618288B2 (en) 2013-12-31
WO2005040169A3 (en) 2006-03-30
ES2319539T3 (es) 2009-05-08
AU2004283196B2 (en) 2011-08-25
US7897771B2 (en) 2011-03-01
DE602004019118D1 (de) 2009-03-05
IL174283A0 (en) 2006-08-01
CA2539426A1 (en) 2005-05-06
EP1668014A2 (en) 2006-06-14
EA200801812A1 (ru) 2009-06-30
CL2009000943A1 (es) 2009-08-21
KR20070023633A (ko) 2007-02-28
BRPI0414541B8 (pt) 2021-05-25
EA010905B1 (ru) 2008-12-30
CA2539426C (en) 2012-07-10
SG146683A1 (en) 2008-10-30
TWI345565B (en) 2011-07-21
SI1668014T1 (sl) 2009-06-30
IS2756B (is) 2011-10-15
NZ545836A (en) 2009-09-25
IL209082A0 (en) 2011-01-31
US20090270370A1 (en) 2009-10-29
US7579470B2 (en) 2009-08-25
US20050119295A1 (en) 2005-06-02
AR047218A1 (es) 2006-01-11
WO2005040169A2 (en) 2005-05-06
US20110040088A1 (en) 2011-02-17
HK1118550A1 (en) 2009-02-13
DK1668014T3 (da) 2009-04-20
ECSP066436A (es) 2006-09-18
KR101151653B1 (ko) 2012-06-28
NI200600094A (es) 2014-02-25
AU2004283196A1 (en) 2005-05-06
US20080103132A1 (en) 2008-05-01
IS8348A (is) 2006-03-09
ATE420881T1 (de) 2009-01-15
BRPI0414541B1 (pt) 2019-02-26
PT1668014E (pt) 2009-03-17
BRPI0414541A (pt) 2006-11-07
IL174283A (en) 2012-06-28
EA200600433A1 (ru) 2006-08-25
JP5069907B2 (ja) 2012-11-07
MXPA06003150A (es) 2006-08-31
US20100016281A1 (en) 2010-01-21
EP1668014B1 (en) 2009-01-14
CN103788089A (zh) 2014-05-14
TW200521123A (en) 2005-07-01
US7402680B2 (en) 2008-07-22

Similar Documents

Publication Publication Date Title
CR8302A (es) Compuestos heterociclicos fusionados
NO2022001I1 (no) Pazopanib
DE60228103D1 (de) Chemische verbindungen
ECSP066549A (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
SV2005001973A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares ref. wyth0090-504 (am101500)
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
BRPI0413449A (pt) compostos de quinoxalina
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
ATE496892T1 (de) Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DK1899334T3 (da) Naphthyridinforbindelser
SE0301650D0 (sv) Novel compounds
UA85563C2 (ru) Конденсированные гетероциклические соединения
AR032548A1 (es) Metodo y composicion para desinfectar una superficie contaminada con una proteina prion
DE60229508D1 (de) Drosophila-stamm, der in diesen übertragene(s) bradeion-gen(e) enthält
CR8009A (es) Compuestos benzo[1,2,5] tiadiazoles
DE60228295D1 (de) Chemische verbindungen
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica
DE60106947D1 (de) Oxindolderivate
ATE437846T1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe
NO20061624L (no) Sammensmeltede heterosykliske forbindelser
MY145145A (en) Fused pyrazole-containing heterocyclic compounds as serotonin receptor modulators
DE50307013D1 (de) Verwendung von hexenal-derivaten als riechstoffe
UY28599A1 (es) Compuestos de pirazolilo e imidazolilo bicíclicos y usos de los mismos
ECSP003846A (es) Pirroles sustituidos